Halozyme Therapeutics, Inc. (NASDAQ:HALO)

CAPS Rating: 3 out of 5

A biopharmaceutical company dedicated to the development and commercialization of recombinant human enzymes for the drug delivery, palliative care, oncology and infertility markets.

Recs

0
Player Avatar pchop123 (76.56) Submitted: 8/21/2012 12:17:48 PM : Outperform Start Price: $5.86 HALO Score: +5.86

Great buy-in point at this time

Featured Broker Partners


Advertisement